

Date: 08 August 2025

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1 G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol: SURAKSHA

Dear Sir / Ma'am,

Sub: Outcome of the Board meeting held today i.e. Friday, 08 August 2025

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time

With further reference to our letter dated 29 July 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Friday, 08 August 2025, has *inter alia*, considered and approved the unaudited (standalone and consolidated) financial results of the Company for the quarter and three months ended 30 June 2025 along with Limited Review Report thereon, issued by the Statutory Auditors of the Company, enclosed herewith as **Annexure-1**.

The meeting of the Board of Directors commenced at 5.40 pm (IST) and concluded at 6:26 pm (IST).

You are requested to kindly take the same on record.

For Suraksha Diagnostic Limited

Mamta Jain
Company Secretary & Compliance Officer


Encl: As above

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited for the quarter ended 30 June 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Company') for the quarter ended 30 June 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Dipak Jaiswal
Membership No.: 063682
UDIN: 25063682BMOTPU7656



Place: Kolkata
Date: 08 August 2025

Suraksha Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter ended 30 June 2025

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30 June 2025 (Unaudited)	31 March 2025 (Audited) (Refer note 3)	30 June 2024 (Audited) (Refer note 4)	31 March 2025 (Audited)
Income				
I Revenue from operations	7,027.90	6,414.51	6,043.29	24,909.54
II Other income	109.57	94.21	121.09	438.30
III Total Income	7,137.47	6,508.72	6,164.38	25,347.84
IV Expenses				
Cost of materials consumed	868.80	858.89	654.12	2,894.54
Employee benefits expenses	1,241.48	999.52	1,018.54	4,190.58
Finance costs	265.85	206.33	221.52	838.53
Depreciation and amortisation expense	915.37	865.93	887.69	3,472.83
Impairment loss	(89.04)	80.23	15.82	218.58
Other expenses	2,622.93	2,493.76	2,244.50	9,346.81
Total expenses (IV)	5,825.39	5,504.66	5,042.19	20,961.87
V Profit before tax and exceptional items (III-IV)	1,312.08	1,004.06	1,122.19	4,385.97
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	1,312.08	1,004.06	1,122.19	4,385.97
VIII Income tax expense				
(i) Current tax	285.67	184.53	309.16	1,066.83
(ii) Tax pertaining to earlier period/years	-	(38.22)	-	(38.22)
(iii) Deferred tax	41.54	57.08	(20.02)	13.36
Total tax expense (VIII)	327.21	203.39	289.14	1,041.97
IX Profit for the period/year (VII-VIII)	984.87	800.67	833.05	3,344.00
X Other comprehensive income				
(a) Items that will not be reclassified subsequently to profit or loss				
(i) Remeasurement gain/(loss) of net defined benefit plan	26.00	(8.47)	(39.73)	(27.25)
(ii) Income tax effect on above	(6.54)	2.13	10.00	6.86
Other comprehensive income/(losses) for the period/year, net of tax	19.46	(6.34)	(29.73)	(20.39)
XI Total comprehensive income for the period/year	1,004.33	794.33	803.32	3,323.61
XII Paid-up equity share capital (face value - ₹2/- per share)				1,041.62
XIII Other equity				20,389.60
XIV Earnings per equity share (Face Value of ₹2/- each)				
- Basic (₹) (not annualised except for year end figures)	1.89	1.54	1.56	6.42
- Diluted (₹) (not annualised except for year end figures)	1.89	1.54	1.56	6.42

Notes to the unaudited standalone financial results

- The standalone financial results for the quarter ended 30 June 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
- These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 08 August 2025. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
- The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter of the financial year.
- The figures for the quarter ended June 30, 2024 have been extracted from the audited special purpose Ind AS Interim standalone financial statements of the Company prepared for the purpose of inclusion in the offer documents.
- The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 - 'Operating Segments'.
- During the quarter ended 31 March 2025, the Company had entered into a Share Subscription Agreement for subscribing to 95,841 equity shares of ₹10/- each representing 16.17% of the total equity share capital of Fetomat Wellness Private Limited ('Fetomat'). Subsequent to financial year ended 31 March 2025, the Company had entered into Share Purchase Agreements ('SPA's') with existing shareholders of Fetomat for acquisition of 2,77,582 equity shares of ₹10/- each representing 46.83% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Company.
- These financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
- Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Place: Kolkata
Date: 08 August 2025

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited for the quarter ended 30 June 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Asian Institute of Immunology & Rheumatology LLP (AIIR)	Subsidiary
3	Suraksha Radiology Private Limited	Subsidiary
4	Suraksha Advanced Radiology Private Limited	Subsidiary



Sr. No	Name of the Entity	Relationship with the Holding Company
5	Fetomat Wellness Private Limited	Subsidiary
6	Suraksha Salvia LLP	Step-down subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of six subsidiaries included in the Statement, whose interim financial statements reflects total revenues of Rs. 290.40 lakhs, total net loss after tax of Rs. 67.24 lakhs and total comprehensive loss of Rs. 67.24 lakhs for the quarter ended 30 June 2025 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and reports of the other auditors.

For M S K A & Associates
Chartered Accountants

ICAI Firm Registration No.105047W



Dipak Jaiswal
Membership No.: 063682
UDIN: 25063682BMOTPV6169



Place: Kolkata
Date: 08 August 2025

Suraksha Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited consolidated financial result for the quarter ended 30 June 2025

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30 June 2025 (Unaudited)	31 March 2025 (Audited) (Refer note 3)	30 June 2024 (Audited) (Refer note 4)	31 March 2025 (Audited)
Income				
I Revenue from operations	7,258.63	6,509.47	6,073.15	25,209.27
II Other income	90.57	81.68	111.69	384.60
III Total Income	7,349.20	6,591.15	6,184.84	25,593.87
IV Expenses				
Cost of materials consumed	875.05	884.80	663.67	2,951.91
Employee benefits expenses	1,277.47	1,020.34	1,037.91	4,289.03
Finance costs	270.49	206.33	221.52	838.53
Depreciation and amortisation expense	948.24	872.88	899.28	3,529.77
Impairment loss	(89.04)	80.23	15.82	218.58
Other expenses	2,820.12	2,605.32	2,295.32	9,625.52
Total expenses (IV)	6,102.33	5,669.90	5,133.52	21,453.34
V Profit before tax and exceptional items (III-IV)	1,246.87	921.25	1,051.32	4,140.53
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	1,246.87	921.25	1,051.32	4,140.53
VIII Income tax expense				
(i) Current tax	287.82	185.30	309.16	1,067.60
(ii) Tax pertaining to earlier years	-	(38.22)	-	(38.22)
(iii) Deferred tax	41.54	57.08	(24.52)	13.36
Total tax expense (VIII)	329.36	204.16	284.64	1,042.74
IX Profit for the period/year (VII-VIII)	917.51	717.09	766.68	3,097.79
X Other comprehensive income				
(a) Items that will not be reclassified subsequently to profit or loss				
(i) Remeasurement gain/(loss) of net defined benefit plan	26.00	(8.47)	(39.73)	(27.25)
(ii) Income tax effect on above	(6.54)	2.13	10.00	6.86
Other comprehensive income/(losses) for the period/year, net of tax	19.46	(6.34)	(29.73)	(20.39)
XI Total comprehensive income for the period/year	936.97	710.75	736.95	3,077.40
XII Profit for the period/year attributed to				
Owners of the parent	939.74	738.87	793.89	3,182.41
Non- controlling interests	(22.23)	(21.78)	(27.21)	(84.62)
	917.51	717.09	766.68	3,097.79
XIII Other comprehensive income for the period/year attributable to				
Owners of the parent	19.46	(6.34)	(29.73)	(20.39)
Non- controlling interests	-	-	-	-
	19.46	(6.34)	(29.73)	(20.39)
XIV Total comprehensive income for the period/year attributable to				
Owners of the parent	959.20	732.53	764.16	3,162.02
Non- controlling interests	(22.23)	(21.78)	(27.21)	(84.62)
	936.97	710.75	736.95	3,077.40
XV Paid-up equity share capital (face value - ₹2/- per share)				1,041.62
XVI Other equity (including Non-controlling interest)				20,082.35
XVII Earnings per equity share (Face Value of ₹2/- each)				
- Basic (₹) (not annualised except for year end figures)	1.80	1.42	1.49	5.97
- Diluted (₹) (not annualised except for year end figures)	1.80	1.42	1.49	5.97

Notes to the unaudited consolidated financial results

- The consolidated financial results for the quarter ended 30 June 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as "the group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
- These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 08 August 2025. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
- The consolidated figures for the quarter ended 31 March 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the financial year.
- The figures for the quarter ended 30 June 2024 have been extracted from the audited special purpose Ind AS Interim Consolidated Financial Statements of the Group prepared for the purpose of inclusion in the offer documents.
- The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –Operating Segments'.
- During the quarter ended 31 March 2025, the Holding Company had entered into a Share Subscription Agreement for subscribing to 95,841 equity shares of ₹10/- each representing 16.17% of the total equity share capital of Fetomat Wellness Private Limited ("Fetomat"). Subsequent to financial year ended 31 March 2025, the Holding Company had entered into Share Purchase Agreements ("SPA's") with existing shareholders of Fetomat for acquisition of 2,77,582 equity shares of ₹10/- each representing 46.83% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Holding Company with effect from 09 April 2025. The purchase price allocation is in progress and therefore, the transaction has been accounted for on a provisional basis as per Ind AS 103.
- These financial results are also available on the Holding Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
- Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 08 August 2025